News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
869,111 Results
Type
Article (87884)
Company Profile (825)
Press Release (780387)
Multimedia
Podcasts (191)
Webinars (28)
Section
Business (233227)
Career Advice (4144)
Deals (39865)
Drug Delivery (145)
Drug Development (91396)
Employer Resources (203)
FDA (18377)
Job Trends (17417)
News (397834)
Policy (39959)
Tag
Academia (3006)
Academic (2)
Accelerated approval (31)
Adcomms (36)
Allergies (142)
Alliances (56981)
ALS (180)
Alzheimer's disease (1783)
Antibody-drug conjugate (ADC) (335)
Approvals (18543)
Artificial intelligence (611)
Autoimmune disease (154)
Automation (34)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (198)
Biotechnology (489)
Bladder cancer (158)
Brain cancer (64)
Breast cancer (644)
Cancer (4905)
Cardiovascular disease (433)
Career advice (3566)
Career pathing (40)
CAR-T (300)
CDC (59)
Celiac Disease (1)
Cell therapy (813)
Cervical cancer (37)
Clinical research (76876)
Collaboration (1743)
Company closure (5)
Compensation (1121)
Complete response letters (70)
COVID-19 (2987)
CRISPR (96)
C-suite (822)
Cystic fibrosis (154)
Data (6131)
Decentralized trials (2)
Denatured (70)
Depression (143)
Diabetes (524)
Diagnostics (7207)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (294)
Drug pricing (219)
Drug shortages (36)
Duchenne muscular dystrophy (232)
Earnings (100029)
Editorial (60)
Employer branding (25)
Employer resources (173)
Events (134943)
Executive appointments (1023)
FDA (21440)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1529)
Gene editing (210)
Generative AI (62)
Gene therapy (657)
GLP-1 (1108)
Government (5432)
Grass and pollen (8)
Guidances (382)
Healthcare (20941)
HIV (60)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (286)
Immuno-oncology (51)
Indications (83)
Infectious disease (3271)
Inflammatory bowel disease (201)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (237)
Interviews (816)
IPO (17952)
IRA (60)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (89)
Layoffs (656)
Leadership (39)
Legal (10156)
Liver cancer (97)
Longevity (14)
Lung cancer (669)
Lymphoma (368)
Machine learning (42)
Management (66)
Manufacturing (815)
MASH (171)
Medical device (14999)
Medtech (15043)
Mergers & acquisitions (22948)
Metabolic disorders (1363)
Multiple sclerosis (157)
NASH (23)
Neurodegenerative disease (340)
Neuropsychiatric disorders (92)
Neuroscience (3061)
NextGen: Class of 2026 (7707)
Non-profit (5107)
Now hiring (62)
Obesity (656)
Opinion (331)
Ovarian cancer (161)
Pain (198)
Pancreatic cancer (224)
Parkinson's disease (288)
Partnered (38)
Patents (488)
Patient recruitment (452)
Peanut (60)
People (66805)
Pharmaceutical (145)
Pharmacy benefit managers (31)
Phase I (23760)
Phase II (33355)
Phase III (25146)
Pipeline (4643)
Policy (328)
Postmarket research (3554)
Preclinical (10680)
Press Release (72)
Prostate cancer (237)
Psychedelics (53)
Radiopharmaceuticals (298)
Rare diseases (862)
Real estate (7437)
Recruiting (80)
Regulatory (28845)
Reports (65)
Research institute (2721)
Resumes & cover letters (651)
Rett syndrome (27)
RNA editing (19)
RSV (83)
Schizophrenia (157)
Series A (254)
Series B (193)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4333)
State (2)
Stomach cancer (20)
Supply chain (111)
Tariffs (98)
The Weekly (119)
Vaccines (1128)
Venture capital (91)
Weight loss (453)
Women's health (84)
Worklife (21)
Date
Today (75)
Last 7 days (875)
Last 30 days (2243)
Last 365 days (33223)
2026 (1424)
2025 (33226)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (87)
Alaska (7)
Arizona (338)
Arkansas (14)
Asia (51479)
Australia (9033)
California (11300)
Canada (3252)
China (1128)
Colorado (476)
Connecticut (491)
Delaware (339)
Europe (118279)
Florida (1653)
Georgia (361)
Hawaii (3)
Idaho (68)
Illinois (938)
India (64)
Indiana (533)
Iowa (23)
Japan (412)
Kansas (132)
Kentucky (42)
Louisiana (29)
Maine (82)
Maryland (1437)
Massachusetts (8367)
Michigan (349)
Minnesota (647)
Mississippi (6)
Missouri (137)
Montana (35)
Nebraska (28)
Nevada (122)
New Hampshire (85)
New Jersey (3057)
New Mexico (33)
New York (2998)
North Carolina (1582)
North Dakota (10)
Northern California (5386)
Ohio (346)
Oklahoma (22)
Oregon (54)
Pennsylvania (2265)
Puerto Rico (20)
Rhode Island (49)
South America (1656)
South Carolina (62)
South Dakota (1)
Southern California (4350)
Tennessee (173)
Texas (1783)
United States (40900)
Utah (339)
Vermont (1)
Virginia (281)
Washington D.C. (85)
Washington State (949)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
There are 869,111 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite antivaccine moves by the Trump administration.
January 14, 2026
·
3 min read
·
Annalee Armstrong
HIV
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of the HIV market and its plans for business development.
January 14, 2026
·
3 min read
·
Dan Samorodnitsky
Neurodegenerative disease
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
January 14, 2026
·
5 min read
·
Heather McKenzie
Press Releases
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
January 14, 2026
·
6 min read
Press Releases
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
January 14, 2026
·
4 min read
Press Releases
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
January 14, 2026
·
8 min read
Press Releases
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio
January 14, 2026
·
7 min read
Opinion
Trump Must Make Biotech Innovation a National Priority
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
January 14, 2026
·
7 min read
·
Cyriac Roeding
Press Releases
Destructed Drug Discovery: How sequence-based AI achieve whole genome screening for billions of small molecule and antibody candidates in hours
January 14, 2026
·
1 min read
Business
JPM26: Novo Refocuses on Diabetes and Obesity Amid Push To Expand GLP-1 Market
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, obesity or overweight.
January 14, 2026
·
3 min read
·
Nick Paul Taylor
1 of 86,912
Next
